BGPT: Paper Review: CRY-NLRP3 complexes define a circadian checkpoint controlling inflammasome activation

Fuel Your Discoveries

Quick Explanation Copied

Core claim (skeptical framing)

The paper proposes that CRY1/CRY2 physically associate with NLRP3 to form circadian protein-level complexes that restrain inflammasome activation, and that these complexes dissociate upon inflammasome stimulation; importantly, the authors further claim circadian time-of-day also modulates NLRP3 inhibitor (MCC950) effectiveness. Evidence in support is multi-assay (co-IP, PLA, functional inflammasome outputs, inhibitor/CRY-stabilizer pharmacology, structural interface mapping, CAPS-relevant variants).

Long Explanation

Paper review: CRY–NLRP3 circadian checkpoint

Last update: Apr 16, 2026

This review focuses on what is directly evidenced in the provided text and extracted figures, what remains mechanistically uncertain, and what could disprove the proposed checkpoint model.

Study thesis (as stated)

CRY1/CRY2 form circadian complexes with NLRP3 that oscillate over time and restrain inflammasome activation; upon stimulation these complexes dissociate and inflammatory outputs rise; CRY stabilization preserves complex formation and blunts inflammasome outputs; and time-of-day modifies MCC950 efficacy, with CAPS-relevant NLRP3 variants altering CRY binding and timing patterns.

1) Circadian anti-phase relationships (readout vs CRY2–NLRP3 proximity)

The paper explicitly reports that inflammasome outputs peak around 17–18 h post-synchronization and show a trough around 29–30 h, while CRY-high correlates with minimal inflammasome activity.

Note: This graph is an anchored schematic (not raw numeric data) to visually encode the paper’s reported peak/trough phases; it intentionally avoids overclaiming quantitative amplitudes because the provided text does not supply full time-series values.

2) Reported circadian acrophases (where peaks occur)

The excerpted figure legend contains explicit acrophase/bathyphase values for multiple readouts, including IL-1β release and ASC speck formation, plus CRY2–NLRP3 interaction.

3) Mechanistic model (what the data support vs what is unresolved)

The data are consistent with a protein-level inhibitory checkpoint in which CRY1/CRY2 associate with NLRP3 in a circadian manner, and inflammasome stimulation reduces CRY-NLRP3 proximity.

Checkpoint diagram

Circadian clock state

CRY1/CRY2 levels & turnover

NLRP3 readiness threshold

At CRY–NLRP3 high phase: CRY1/CRY2 associate with NLRP3 → restrains inflammasome assembly/activation → ↓ caspase-1 activation, ↓ ASC specks, ↓ IL-1β, ↓ pyroptosis.

Upon stimulation (nigericin): CRY proteins decrease and CRY–NLRP3 proximity drops → inhibition is relieved → inflammasome activation rises.

Pharmacology: CRY stabilizers (KL001/KL044/TH301) preserve CRY–NLRP3 association after nigericin and attenuate inflammasome outputs; MCC950 suppresses NLRP3 readouts and shows circadian/time-of-day dependence in efficacy.

4) Interface mapping: what is structural/model-supported

The paper maps the NLRP3 region binding CRYs to NACHT+LRR on NLRP3 and CRY PHR on the cryptochrome proteins using truncations/co-IP. It then uses AlphaFold modeling and structural alignment to infer a contact interface and compares RMSD/PAE confidence with published structures including NLRP3–CRID3 inhibitor complex (7PZC) and a mouse CRY2–FBXL3/SKP1 complex (4I6J).

Confidence note (skeptical)

AlphaFold-based interfaces can be informative but not equivalent to experimental binding surfaces; the excerpted text itself notes low inter-chain confidence and flexibility (high PAE), so the interface should be treated as a testable hypothesis awaiting biochemical/structural validation (e.g., alanine scanning + binding kinetics, or cryo-EM/HDX-style validation).

5) CAPS-relevant NLRP3 variants: do they weaken CRY binding and shift timing?

The excerpted results describe: (i) interface-positioned LRR variants (e.g., M701T, Q703K; with note that pathogenicity may be debated for some) and (ii) pathogenic NACHT gain-of-function variants (e.g., R168Q, R260W, V262G, D303N) reduce CRY2 binding to NLRP3 in co-IP assays; additionally, several variants reduce CRY2 abundance with variant-dependent magnitude (notably V262G).

This plot is intentionally non-numeric and uses an index only to reflect the text’s qualitative ordering (e.g., V262G emphasized as producing the most pronounced CRY2 abundance decrease). It should not be used as quantitative evidence.

6) Skeptical critique: what is strong, what is plausible, what is uncertain

What looks strong (multi-evidence triangulation)

Convergent functional readouts: the authors measure ASC speck formation, IL-1β secretion/processing, caspase-1 activity, and pyroptosis/cell death (DRAQ7 incorporation). Multi-readout agreement reduces the chance that timing effects are an assay artifact.
Association-to-function bridge: CRY–NLRP3 association is probed by co-IP and PLA in myeloid and cell models, and functional inhibition occurs when CRY is stabilized pharmacologically.
Time-of-day modulation of drug response is experimentally addressed (MCC950 efficacy varies across timepoints and differs by genotype in the U937 variant system).

What remains uncertain / potential confounders

Causality of complex dissociation vs CRY degradation: the discussion states the causal order between CRY–NLRP3 dissociation and CRY destabilization remains unresolved (whether FBXL3-mediated turnover is required for release of inhibition, or whether dissociation precedes degradation).
Protein-level association ≠ direct binding geometry: PLA/co-IP support proximity/complexing but do not by themselves guarantee a direct physical interface; the paper itself uses truncation and structural prediction, but direct biochemical binding kinetics (e.g., purified proteins) are not shown in the excerpted text.
CRY stabilizers may have off-target effects: the authors use KL001/KL044/TH301 and show preservation of CRY abundance/association and reduced inflammasome outputs, but stabilization could affect additional CRY-dependent pathways. The text links AMPK-dependent phosphorylation to CRY1 turnover in the nigericin context, but broader signaling effects are not fully enumerated in the excerpt.
Modeling uncertainty: AlphaFold inter-chain confidence is reported as low/modest, consistent with flexible relative orientations; without experimental structure, interface residues should be treated as candidate hypotheses.

Context: circadian regulation of immunity (why this is plausible)

The introduction positions the work within evidence that circadian clocks regulate immune function broadly, including trafficking and inflammatory responses, and that macrophages show intrinsic daily oscillations in inflammatory mediators.

The paper also contrasts its mechanism (protein-level checkpoint at NLRP3 complex formation/activation) with the more commonly emphasized transcriptional and metabolic circadian mechanisms. The anti-phase relationship and rapid dissociation are consistent with a protein-level gating layer, but—as noted above—direct binding and causal ordering still need further resolution.

Author reviews (click to open BGPT author-specific reviews)

Feedback:

Updated: April 16, 2026